The Asia Pacific AI In Drug Repurposing Market would witness market growth of 20.5% CAGR during the forecast period (2025-2032).
The China market dominated the Asia Pacific AI In Drug Repurposing Market by Country in 2024, and would continue to be a dominant market till 2032; thereby, achieving a market value of $310.2 million by 2032. The Japan market is registering a CAGR of 19.7% during (2025 - 2032). Additionally, The India market would showcase a CAGR of 21.3% during (2025 - 2032). The China and Japan led the Asia Pacific AI In Drug Repurposing Market by Country with a market share of 38.4% and 18.4% in 2024. The Malaysia market is expected to witness a CAGR of 24.5% during throughout the forecast period.
The Asia Pacific AI-driven drug repurposing industry has grown quickly along with the region's growing biotechnology, genomics, and digital health infrastructure. At first, the field was disorganized and mostly academic. But it has grown thanks to improvements in cloud computing, biomedical databases, and government support in China, India, Japan, South Korea, and Southeast Asia. Today, local biotech companies combine AI with clinical and pharmacological data, thanks to government programs that encourage the use of AI in biotech. Asia Pacific has gone from being a user of AI repurposing technologies to a producer of cutting-edge, regionally tailored platforms thanks to strategic partnerships with hospitals, innovation agencies, and global pharmaceutical companies.
This growth is driven by three main trends: a focus on diseases that have been ignored or are specific to certain areas, the use of federated modeling to get around data privacy issues, and a rise in cross-border partnerships for validation and commercialization. Companies stay competitive by vertically integrating with health systems, focusing on specific therapeutic areas in their region, and working with pharmaceutical companies to develop new drugs or license existing ones. Even though competition isn't the same in all countries, the market is coming together around companies with strong AI knowledge, local clinical integration, and regulatory compliance. This shows a shift from algorithmic innovation to trust, explainability, and deep embedding in the healthcare ecosystem.
Based on Technology, the market is segmented into Machine Learning/Deep Learning, Natural Language Processing (NLP), Knowledge Graphs & Network-Based AI, Generative AI & Large Language Models (LLMs), and Computer Vision. The Machine Learning/Deep Learning market segment dominated the China AI In Drug Repurposing Market by Technology is expected to grow at a CAGR of 17.7 % during the forecast period thereby continuing its dominance until 2032. Also, The Computer Vision market is anticipated to grow as a CAGR of 23.3 % during the forecast period during (2025 - 2032).
Free Valuable Insights: The AI In Drug Repurposing Market is Predicted to reach USD 4.11 Billion by 2032, at a CAGR of 19.7%
Based on Application, the market is segmented into Oncology, Neurology, Infectious Diseases, Rare & Orphan Diseases, Cardiology, and Other Application. Among various Singapore AI In Drug Repurposing Market by Application; The Oncology market achieved a market size of USD $3.7 Million in 2024 and is expected to grow at a CAGR of 21.1 % during the forecast period. The Cardiology market is predicted to experience a CAGR of 23.8% throughout the forecast period from (2025 - 2032).
China is quickly becoming a major center for AI-driven drug repurposing. This is thanks to strong government programs like Healthy China 2030 and Made in China 2025, a lot of healthcare data, and more biotech innovation. The country's large electronic health records, genomic data, and high-performance computing infrastructure make it possible to do large-scale AI modeling. Startups in the country and partnerships with companies around the world make the country more competitive. AI platforms use multi-omics and real-world evidence to speed up drug translation in areas like oncology, cardiovascular, metabolic, and infectious diseases. China's size, funding ecosystem, and changing policy landscape make it well-positioned to lead AI-enabled drug repurposing across the Asia Pacific, even though data governance, interoperability, and regulatory adaptation are still problems.
By Component
By Technology
By End Use
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 